Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Richeldi

Showing results (161-170 of 356) with videos related to

Pageof 36
Sort By:
BMC Pulmonary Medicine|January 10, 2020
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosisLuca Richeldi, Martin Kolb, Stéphane Jouneau, et al.
American Journal of Respiratory and Critical Care Medicine|March 19, 2016
Precision Medicine: The New Frontier in Idiopathic Pulmonary FibrosisRobert Brownell, Naftali Kaminski, Prescott G Woodruff, et al.
Multidisciplinary Respiratory Medicine|March 15, 2019
Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: preliminary resultsAndrea Smargiassi, Riccardo Inchingolo, Marco Chiappetta, et al.
Respiratory Medicine|August 13, 2019
Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanibLuca Richeldi, Bruno Crestani, Arata Azuma, et al.
The European Respiratory Journal|January 26, 2023
Idiopathic pulmonary fibrosis: state of the art for 2023Anna J Podolanczuk, Carey C Thomson, Martine Remy-Jardin, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2004
T cell-based tracking of multidrug resistant tuberculosis infection after brief exposureLuca Richeldi, Katie Ewer, Monica Losi, et al.
Annals of the American Thoracic Society|February 6, 2023
Summary for Clinicians: Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in AdultsDerrick D Herman, Marya Ghazipura, Ganesh Raghu, et al.
The Cochrane Database of Systematic Reviews|September 9, 2010
Non-steroid agents for idiopathic pulmonary fibrosisPaolo Spagnolo, Cinzia Del Giovane, Fabrizio Luppi, et al.
Chest|December 12, 2018
Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating BiomarkersGanesh Raghu, Luca Richeldi, Alexandre Jagerschmidt, et al.
BMJ Open Respiratory Research|June 11, 2019
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trialsLisa Lancaster, Bruno Crestani, Paul Hernandez, et al.
Pageof 36

Showing results (161-170 of 356) with videos related to

Sort By:
Pageof 36
BMC Pulmonary Medicine|January 10, 2020
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosisLuca Richeldi, Martin Kolb, Stéphane Jouneau, et al.
American Journal of Respiratory and Critical Care Medicine|March 19, 2016
Precision Medicine: The New Frontier in Idiopathic Pulmonary FibrosisRobert Brownell, Naftali Kaminski, Prescott G Woodruff, et al.
Multidisciplinary Respiratory Medicine|March 15, 2019
Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: preliminary resultsAndrea Smargiassi, Riccardo Inchingolo, Marco Chiappetta, et al.
Respiratory Medicine|August 13, 2019
Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanibLuca Richeldi, Bruno Crestani, Arata Azuma, et al.
The European Respiratory Journal|January 26, 2023
Idiopathic pulmonary fibrosis: state of the art for 2023Anna J Podolanczuk, Carey C Thomson, Martine Remy-Jardin, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2004
T cell-based tracking of multidrug resistant tuberculosis infection after brief exposureLuca Richeldi, Katie Ewer, Monica Losi, et al.
Annals of the American Thoracic Society|February 6, 2023
Summary for Clinicians: Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in AdultsDerrick D Herman, Marya Ghazipura, Ganesh Raghu, et al.
The Cochrane Database of Systematic Reviews|September 9, 2010
Non-steroid agents for idiopathic pulmonary fibrosisPaolo Spagnolo, Cinzia Del Giovane, Fabrizio Luppi, et al.
Chest|December 12, 2018
Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating BiomarkersGanesh Raghu, Luca Richeldi, Alexandre Jagerschmidt, et al.
BMJ Open Respiratory Research|June 11, 2019
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trialsLisa Lancaster, Bruno Crestani, Paul Hernandez, et al.
Pageof 36